Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Proteinuria D011507 30 associated lipids
Pregnancy Complications, Hematologic D011250 11 associated lipids
Pregnancy Complications, Cardiovascular D011249 11 associated lipids
Pregnancy Complications D011248 19 associated lipids
Adenomatous Polyposis Coli D011125 16 associated lipids
Polycythemia Vera D011087 13 associated lipids
Pneumonia, Viral D011024 3 associated lipids
Pneumonia, Aspiration D011015 3 associated lipids
Pneumonia D011014 10 associated lipids
Pleurisy D010998 20 associated lipids
Platelet Storage Pool Deficiency D010981 3 associated lipids
Placenta Diseases D010922 5 associated lipids
Periapical Periodontitis D010485 6 associated lipids
Peptic Ulcer D010437 19 associated lipids
Pain, Postoperative D010149 13 associated lipids
Pain D010146 64 associated lipids
Ovarian Neoplasms D010051 10 associated lipids
Oligomenorrhea D009839 1 associated lipids
Obesity, Morbid D009767 8 associated lipids
Neutropenia D009503 15 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Nephritis D009393 19 associated lipids
Nasal Polyps D009298 26 associated lipids
Myocardial Infarction D009203 21 associated lipids
Mucocutaneous Lymph Node Syndrome D009080 9 associated lipids
Mixed Connective Tissue Disease D008947 2 associated lipids
Migraine Disorders D008881 11 associated lipids
Menorrhagia D008595 4 associated lipids
Meningioma D008579 11 associated lipids
Mastocytosis D008415 5 associated lipids
Mastitis, Bovine D008414 8 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Magnesium Deficiency D008275 9 associated lipids
Macular Edema D008269 3 associated lipids
Lupus Nephritis D008181 8 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Lung Diseases D008171 37 associated lipids
Liver Diseases, Alcoholic D008108 13 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Leukopenia D007970 9 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Leukemia, Lymphoid D007945 18 associated lipids
Leiomyosarcoma D007890 4 associated lipids
Polycystic Kidney Diseases D007690 12 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Kidney Diseases D007674 29 associated lipids
Keratitis D007634 7 associated lipids
Jejunal Diseases D007579 3 associated lipids
Intermittent Claudication D007383 6 associated lipids
Influenza, Human D007251 11 associated lipids
Inflammation D007249 119 associated lipids
Infertility D007246 3 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Hypothyroidism D007037 32 associated lipids
Hypotension D007022 41 associated lipids
Hypolipoproteinemias D007009 9 associated lipids
Hypertension, Renovascular D006978 10 associated lipids
Hypertension, Renal D006977 9 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Hypertension, Portal D006975 12 associated lipids
Hypertension D006973 115 associated lipids
Hypersensitivity D006967 22 associated lipids
Hyperlipoproteinemia Type IV D006953 6 associated lipids
Hyperlipoproteinemias D006951 15 associated lipids
Hyperlipidemias D006949 73 associated lipids
Hyperemia D006940 25 associated lipids
Hyperlipoproteinemia Type II D006938 22 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hypercapnia D006935 5 associated lipids
Hyperalgesia D006930 42 associated lipids
Hyperaldosteronism D006929 4 associated lipids
Hydatidiform Mole D006828 3 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemorrhagic Fever with Renal Syndrome D006480 3 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Hemolysis D006461 131 associated lipids
Heart Valve Diseases D006349 4 associated lipids
Heart Septal Defects D006343 2 associated lipids
Heart Failure D006333 36 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Rhinitis, Allergic, Seasonal D006255 7 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Glomerulonephritis, IGA D005922 7 associated lipids
Glomerulonephritis D005921 35 associated lipids
Glioma D005910 112 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Gastritis D005756 27 associated lipids
Frostbite D005627 1 associated lipids
Foot Rot D005535 1 associated lipids
Fistula D005402 8 associated lipids
Fibrosis D005355 23 associated lipids
Fibromuscular Dysplasia D005352 2 associated lipids
Fever D005334 35 associated lipids
Fetal Diseases D005315 8 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Nell A et al. [Collection, preparation and storage of human plasma for radioimmunologic determination of thromboxane B2]. 1988 Wien. Klin. Wochenschr. pmid:3242305
Kaliman J et al. [Venous prostacycline synthesis and plasma thromboxane B2 after low-dose aspirin]. 1983 Wien. Klin. Wochenschr. pmid:6359724
Wirthumer-Hoche C and Sinzinger H [Protein binding of thromboxane--one of the sources of error in thromboxane determination]. 1985 Wien. Klin. Wochenschr. pmid:3993037
Sinzinger H et al. [Defects in the prostaglandin system. IX. Lipoxygenase defect of thrombocytes in a patient with polycythemia vera]. 1990 Wien. Klin. Wochenschr. pmid:2107637
Burghuber OC et al. Hydrogen peroxide induced pulmonary vasoconstriction in isolated rat lungs is attenuated by U60,257, a leucotriene synthesis blocker. 1986 Wien. Klin. Wochenschr. pmid:3518246
Gorczynska E et al. [Effect of various stimulators on cyclooxygenase activity, platelet aggregation and TxB2 synthesis after using a platelet inhibitor (Aspro Clear) in vivo and in vitro]. 1985 Wiad. Lek. pmid:3933184
Glushko LV et al. [An evaluation of the efficacy of antiatherosclerotic agents based on a study of the peripheral blood monocytes]. 1990 Vrach Delo pmid:2168603
Efimov VV and LadnyÄ­ AI [Status of the prostacyclin and thromboxane system, lipid metabolism and lipid peroxidation processes in patients with coronary atherosclerosis]. 1986 Vrach Delo pmid:3754994
Aliavi AL [Thrombocyte function and the prostacyclin-thromboxane system in patients with acute myocardial infarct]. 1988 Vrach Delo pmid:3293319
Bagdasarian A et al. IVIG adverse reactions: potential role of cytokines and vasoactive substances. 1998 Vox Sang. pmid:9501404
Jacobi K et al. Plasma levels of eicosanoids after transfusion of intraoperatively salvaged blood. 2000 Vox Sang. pmid:10729809
Bassalyk LS et al. [The effect of indomethacin and leukinferon on the thromboxane B2 level in the blood plasma of patients with endometrial cancer in the perioperative period]. 1992 Vopr Onkol pmid:1300754
Malý J et al. [Changes in platelet function in patients with arterial hypertension]. 1995 Vnitr Lek pmid:7571480
Spinarová L et al. [Physical training in patients with chornic heart failure: haemodynamics, effects]. 2001 Vnitr Lek pmid:15635849
Margolis JH et al. The efficacy of dexamethasone and flunixin meglumine in treating endotoxin-induced changes in calves. 1987 Vet. Res. Commun. pmid:3445446
Atroshi F et al. Inflammation-related changes in cyclic AMP and cyclic GMP in bovine mastitis. 1989 Vet. Res. Commun. pmid:2561035
Cheng Z et al. Pharmacokinetic and pharmacodynamic studies on phenylbutazone and oxyphenbutazone in goats. 1997 Vet. Rec. pmid:9123796
Friton GM et al. Clinical and anti-inflammatory effects of treating endotoxin-challenged pigs with meloxicam. 2006 Vet. Rec. pmid:17056651
McKellar QA et al. Flunixin pharmacokinetics and serum thromboxane inhibition in the dog. 1989 Vet. Rec. pmid:2763429
Galbraith EA and McKellar QA Pharmacokinetics and pharmacodynamics of piroxicam in dogs. 1991 Vet. Rec. pmid:1887556
Mustonen K et al. Dose-response investigation of oral ketoprofen in pigs challenged with Escherichia coli endotoxin. 2012 Vet. Rec. pmid:22735989
Banting A et al. Efficacy of oral and parenteral ketoprofen in lactating cows with endotoxin-induced acute mastitis. 2008 Vet. Rec. pmid:18953074
Taylor PM et al. Pharmacodynamics and pharmacokinetics of flunixin in the cat: a preliminary study. 1991 Vet. Rec. pmid:2035219
Giri SN et al. Effects of endotoxin infusion on circulating levels of eicosanoids, progesterone, cortisol, glucose and lactic acid, and abortion in pregnant cows. 1990 Vet. Microbiol. pmid:2407024
Van de Weerdt ML et al. Ketoprofen and phenylbutazone attenuation of PAF-induced lung inflammation in calves. 1999 Vet. J. pmid:10030127
Lees P et al. Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. 1998 Vet. J. pmid:9638074
Maddens BE et al. Validation of immunoassays for the candidate renal markers C-reactive protein, immunoglobulin G, thromboxane B2 and retinol binding protein in canine urine. 2010 Vet. Immunol. Immunopathol. pmid:19815297
Hall JA et al. Dietary fish oil alters the lysophospholipid metabolomic profile and decreases urinary 11-dehydro thromboxane Bâ‚‚ concentration in healthy Beagles. 2011 Vet. Immunol. Immunopathol. pmid:21925741
Sigel MM et al. Phylogenetic studies on lymphokines. Fish lymphocytes respond to human IL-1 and epithelial cells produce an IL-1 like factor. 1986 Vet. Immunol. Immunopathol. pmid:3490047
Peters SM et al. In vivo characterization of inflammatory biomarkers in swine and the impact of flunixin meglumine administration. 2012 Vet. Immunol. Immunopathol. pmid:22648045
Bailey SR et al. Plasma concentrations of endotoxin and platelet activation in the developmental stage of oligofructose-induced laminitis. 2009 Vet. Immunol. Immunopathol. pmid:19091426
Moore RM et al. Effect of platelet-activating factor antagonist L-691,880 on low-flow ischemia-reperfusion injury of the large colon in horses. 1998 Jan-Feb Vet Surg pmid:9449176
Higgins AJ et al. Actions of BW540C in an equine model of acute inflammation: a preliminary study. 1987 Vet Q pmid:3039716
Dinev D and Andonova M The effect of general anesthesia and abdominal surgery upon plasma thromboxane B concentrations in horses. 2004 Vet Anaesth Analg pmid:15053753
Mullins KB et al. Effects of carprofen, meloxicam and deracoxib on platelet function in dogs. 2012 Vet Anaesth Analg pmid:22248445
Brezitskaia ON and Sedov KR [Status of the thrombocytic-vascular component of the hemostasis system in the population of the Far North]. 1991 Vestn. Akad. Med. Nauk SSSR pmid:1801462
Polkanov VS and Vinogradov AI [The content of thromboxane B2 and 6-ketoprostaglandin F1 alpha of the blood plasma in patients with psoriasis and children with allergic dermatoses]. 1989 Vestn Dermatol Venerol pmid:2718610
Zhou Z et al. Mechanisms underlying uridine adenosine tetraphosphate-induced vascular contraction in mouse aorta: Role of thromboxane and purinergic receptors. 2015 Vascul. Pharmacol. pmid:25921923
Miyamoto A et al. Ibuprofen or ozagrel increases NO release and l-nitro arginine induces TXA(2) release from cultured porcine basilar arterial endothelial cells. 2007 Vascul. Pharmacol. pmid:17113355
González-Correa JA et al. Gender differences in the effect of aspirin on retinal ischemia, prostanoid synthesis and nitric oxide production in experimental type 1-like diabetes. 2007 Aug-Sep Vascul. Pharmacol. pmid:17581795
Park WH et al. Anti-inflammatory effects of a traditional Korean herbal formulation, Silsosangami, consisting of seven medicinal herbs: effect on hemolysis, neutrophil function, and gene expressions of iNOS and COX-2. 2004 Vascul. Pharmacol. pmid:15664882
Sinzinger H et al. 20 mg aspirin daily--evidence for a clinical future of this extremely low-dose in arterial disease? 1988 VASA pmid:3369232
Strobl-Jäger E et al. Platelet half-life in comparison to other in-vivo platelet function parameters such as thromboxane B2, beta-thromboglobulin and platelet factor 4 in patients with atherosclerotic lesions with and without hyperlipoproteinemia. 1986 VASA pmid:2948337
Ditter H and Matthias FR Changes in thromboxane formation by platelets during and after a continuous endotoxin infusion into rabbits. 1984 VASA pmid:6516562
Fitscha P et al. Follow-up of in-vivo platelet function (platelet half-life, thromboxane B2) in patients with coronary heart disease. 1984 VASA pmid:6516563
Rebrov BA [Role of thromboxane A2 (B2) in the pathogenesis of stress proteinuria in healthy persons]. 2001 Mar-Apr Urologiia pmid:11490711
Frøkiaer J et al. Renal blood flow and pelvic pressure after 4 weeks of total upper urinary tract obstruction in the pig. The effect of a TxA2 synthetase inhibitor on active preglomerular vasoconstriction. 1988 Urol. Res. pmid:3413908
Ali M et al. Urothelial synthesis of prostanoids in the ovine ureter. 1998 Urol. Res. pmid:9694598
Greenstein A et al. The role of oxygen free radicals and prostaglandins in reperfusion injury to warm ischemic kidneys. 1991 Urol. Res. pmid:1759334
RogovyÄ­ IuE [Beta 2-microglobulin as a criterion of dysfunction in the regulation of proximal tubular activity in mercuric chloride-induced nephropathy]. 1998 May-Jun Urol Nefrol (Mosk) pmid:9644989
Jokela R et al. Effect of in vitro stability of dietary fish oil on lipid peroxidation and prostanoids in vivo. 1998 Ups. J. Med. Sci. pmid:10052110
Persico N et al. Transdermal HRT and Doppler findings in normotensive and hypertensive postmenopausal patients. 2005 Ultrasound Obstet Gynecol pmid:16184506
Komarevtseva IA et al. [Change in prostanoid metabolism in cystic kidney lesion]. 1997 Sep-Dec Ukr. Biokhim. Zh. pmid:9606841
Midttun M et al. [Thrombocyte aggregation and serum thromboxane in patients with acute myocardial infarction]. 1990 Ugeskr. Laeg. pmid:2275044
Lyck F et al. [Thrombocyte aggregation and serum thromboxane B2 in patients with unstable angina pectoris treated with diltiazem or verapamil]. 1992 Ugeskr. Laeg. pmid:1462402
Weir MR et al. Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production of healthy humans. 1990 Transplantation pmid:2301025
Nassiri M et al. Lymphoid organ production of immunomodulatory eicosanoids in mice resistant to neonatal tolerance induction. 1994 Transplantation pmid:8009599
Coffman TM et al. Effect of dietary fish oil supplementation on eicosanoid production by rat renal allografts. 1988 Transplantation pmid:3125638
Ogata K et al. Attenuation of ischemia and reperfusion injury of canine livers by inhibition of type II phospholipase A2 with LY329722. 2001 Transplantation pmid:11374398
Lane NJ et al. Inhibition of leukotriene B4 synthesis does not prevent development of acute renal failure following storage and transplantation. 1994 Transplantation pmid:7809921
Ramos E et al. The impact of arterialization on prostanoid generation after liver transplantation in the rat. 1994 Transplantation pmid:8042232
Fan TP et al. Mechanism of action of cyclosporine in preventing cardiac allograft rejection. II. Graft tissue levels of prostacyclin and thromboxane. 1987 Transplantation pmid:3547787
Kawaguchi A et al. Urinary thromboxane excretion in cardiac allograft rejection in immunosuppressed rats. 1987 Transplantation pmid:3547788
Capitanio A et al. Detection of circulating released platelets after renal transplantation. 1982 Transplantation pmid:6461116
Gibbons CP et al. Cortical and vascular prostaglandin synthesis during renal allograft rejection in the rat. 1987 Transplantation pmid:3554639
Garvin PJ et al. Evaluation of the thromboxane A2 synthetase inhibitor OKY-046 in a warm ischemia-reperfusion rat model. 1996 Transplantation pmid:8633364
Balkhy HH et al. Comparison of Eurocollins and University of Wisconsin solution in single flush preservation of the ischemic reperfused lung: an in vivo rabbit model. 1995 Transplantation pmid:7732552
Markewitz A et al. Reduction of cyclosporine-induced nephrotoxicity by cilastatin following clinical heart transplantation. 1994 Transplantation pmid:8154033
Kim YI et al. Hepatoprotection by a PGI2 analogue in complete warm ischemia of the pig liver. Prostanoid release from the reperfused liver. 1994 Transplantation pmid:7940729
Khirabadi BS et al. Urine immunoreactive thromboxane B2 in rat cardiac allograft rejection. 1985 Transplantation pmid:3880966
Textor SC et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. 1993 Transplantation pmid:7685934
Petric R et al. Amelioration of experimental cyclosporine nephrotoxicity by calcium channel inhibition. 1992 Transplantation pmid:1465778
Johnson BF et al. Urinary thromboxane and 6-keto-prostaglandin F1 alpha are early markers of acute rejection in experimental pancreas transplantation. 1994 Transplantation pmid:7518618
Smith SR et al. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. 1993 Transplantation pmid:8279014
Johnson BF et al. Thromboxane and prostacyclin synthesis in experimental pancreas transplantation. Changes in parenchymal and vascular prostanoids. 1993 Transplantation pmid:8279018
Proppe DG et al. Diagnostic value of urinary thromboxane B2 concentration in detection of initial acute rejection reactions in human renal allografts. 1995 Transplantation pmid:7709445
Youngelman DF et al. Effects of chronic cyclosporine administration on renal blood flow and intrarenal blood flow distribution. 1991 Transplantation pmid:1994546
Elzinga L et al. Modification of experimental nephrotoxicity with fish oil as the vehicle for cyclosporine. 1987 Transplantation pmid:3810835
Coffman TM et al. Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. 1987 Transplantation pmid:3810836
Gladue RP and Newborg MF The protective effects of the thromboxane synthetase inhibitor Dazmegrel on nephrotoxicity in cyclosporine-treated rats. 1991 Transplantation pmid:1949170
Santillan-Doherty P et al. Urinary thromboxane B2 as an indicator of acute rejection in lung allotransplantation. 1988 Transplantation pmid:3285529
Post S et al. Rapid increase in the activity of enzymes of eicosanoid synthesis in hepatic and extrahepatic tissues after experimental liver transplantation. 1991 Transplantation pmid:1903222
García-Valdecasas JC et al. Prostacyclin, thromboxane, and oxygen free radicals and postoperative liver function in human liver transplantation. 1995 Transplantation pmid:7570973
Hotter G et al. Nitric oxide and arachidonate metabolism in ischemia-reperfusion associated with pancreas transplantation. 1995 Transplantation pmid:7871573
Moore TC et al. Depression of peripheral lymph node lymphocyte traffic in sheep following central venous allogeneic whole-blood transfusion. 1990 Transplantation pmid:1970202
Suckfüll MM et al. The contribution of endothelial cells to hyperacute rejection in xenogeneic perfused working hearts. 1994 Transplantation pmid:8310518
Post S et al. Prostanoid release in experimental liver transplantation. 1990 Transplantation pmid:2316009
Schnabel FR et al. The relationship of urinary thromboxane excretion to cyclosporine nephrotoxicity. 1991 Transplantation pmid:2006526
Ku K et al. Influences of dietary omega-3 polyunsaturated fatty acids on the recovery of cardiac and renal functions after preservation in hyperlipidemic rats. 1997 Transplantation pmid:9275102
Klassen DK et al. Effects of cyclosporine on human renal allograft renin and prostaglandin production. 1989 Transplantation pmid:2660347
Ruiz P et al. Evidence that pretransplant donor blood transfusion prevents rat renal allograft dysfunction but not the in situ cellular alloimmune or morphologic manifestations of rejection. 1988 Transplantation pmid:3276038
Kawaguchi A et al. Increase in urinary thromboxane B2 in rats caused by cyclosporine. 1985 Transplantation pmid:4024243
Pfeiffer S et al. Hyperacute lung rejection in the pig-to-human model. III. Platelet receptor inhibitors synergistically modulate complement activation and lung injury. 2003 Transplantation pmid:12698079
Foegh ML et al. Thromboxane and inflammatory cell infiltration of the allograft of renal transplant patients. 1987 Transplant. Proc. pmid:3313875
Su CL et al. Inducible cyclooxygenase expression mediating hypoxia/reoxygenation-induced pulmonary vasoconstriction is attenuated by a cyclooxygenase inhibitor in rats. 2012 Transplant. Proc. pmid:22564588
WÅ‚odarczyk Z et al. Effects of pentoxifylline treatment on delayed graft function in cadaveric kidney recipients. 2000 Transplant. Proc. pmid:10995988
Urade M et al. Changes of thromboxane B2 level in experimental orthotopic liver transplantation in swines--the effect of warm ischemia and thromboxane A2 synthetase inhibition. 1992 Transplant. Proc. pmid:1496677
Pratschke J et al. Allogeneic heart transplantation following xenografting. 1992 Transplant. Proc. pmid:1566482
Sinzinger H et al. Platelet-derived growth factor and prostacyclin in kidney transplant rejection. 1987 Transplant. Proc. pmid:3303560
Foegh ML et al. Differential effect of CGS 13080, a thromboxane synthase inhibitor, in suppressing serum and urine immunoreactive thromboxane B2 in kidney transplant patients. 1988 Transplant. Proc. pmid:3279631